Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oral compound pharmaceutic preparation containing tranilast and salbutamol

A pharmaceutical preparation, the technology of salbutamol, which is applied in the field of preparing oral therapeutic agents for asthma, can solve the problems of slow release, difficulty in achieving complete release, and affecting drug efficacy, etc.

Inactive Publication Date: 2010-03-31
沈阳三川医药科技有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] At present, the compound preparations of tranilast and albuterol sulfate for clinical use are only ordinary tablets and capsules, which are released slowly in the body after oral administration, and it is difficult to achieve complete release, which leads to a decrease in the bioavailability of the drug, thus making it effective. It is relatively slow, which affects the full play of the drug effect, and cannot achieve the ideal anti-asthma effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral compound pharmaceutic preparation containing tranilast and salbutamol

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1: compound tranilast dispersible tablet

[0021] 【prescription】

[0022] Tranilast 80.0g

[0023] Salbutamol Sulfate 2.4g

[0024] Starch 81.5g

[0025] Microcrystalline Cellulose 20.0g

[0026] Low-substituted hydroxypropyl cellulose 2.0g

[0027] Sodium carboxymethyl starch 8.0g

[0028] Magnesium Stearate 1.0g

[0029] 5% starch slurry 99.0g

[0030]

[0031] Makes 1000 pieces

[0032] 【Preparation Process】

[0033] All raw and auxiliary materials were crushed through a 100-mesh sieve for later use, and 5% starch slurry was prepared for later use; Tranilast, albuterol sulfate, low-substituted hydroxypropyl cellulose, sodium hydroxymethyl starch, microcrystalline cellulose, and starch were fully mixed and uniform , add 5% starch slurry to moisten, pass through a 18-mesh sieve, dry at 50°C until dry, pass through a 20-mesh sieve for granulation, add magnesium stearate, mix evenly, and press into tablets to...

Embodiment 2

[0040] Embodiment 2: compound tranilast chewable tablet

[0041] 【prescription】

[0042] Tranilast 80.0g

[0043] Salbutamol Sulfate 2.4g

[0044] Mannitol 200.0g

[0045] Microcrystalline Cellulose 80.0g

[0046] Sodium Saccharin 2.0g

[0047] Spearmint oil 0.1g

[0048] Magnesium Stearate 5.0g

[0049] 5% polyethylene glycol 6000 ethanol (50%) solution

[0050]

[0051] Made into 1000.0 pieces

[0052] 【Preparation Process】

[0053] Grind the raw materials and auxiliary materials through an 80-mesh sieve for later use; mix tranilast and mannitol evenly in equal increments, and pass through a 60-mesh sieve twice for later use; dissolve salbutamol and sodium saccharin in a small amount of distilled water Then mix it with quantitative 3% hydroxypropyl methylcellulose as a binder. Use the above-mentioned binder to make soft materials, make granules with a 16-mesh sieve, and dry at 60°C to obtain dry granules. The...

Embodiment 3

[0058] Embodiment 3: compound tranilast effervescent tablet

[0059] 【prescription】

[0060] Tranilast 80.0g

[0061]Salbutamol Sulfate 2.4g

[0062] Citric acid 80.0g

[0063] Lactose 44.0g

[0064] Natural Orange Flavor 1.5ml

[0065] Sodium bicarbonate (fine powder) 75.0g

[0066] Magnesium Stearate 3.0g

[0067] 5% polyvinylpyrrolidone K30 appropriate amount

[0068]

[0069] Makes 1000 pieces

[0070] 【Preparation Process】

[0071] The raw and auxiliary materials in the prescription were crushed separately and passed through a 80-mesh sieve for later use; Tranilast, salbutamol sulfate, citric acid, etc. were fully mixed according to the amount of the prescription, and mixed through a 60-mesh sieve twice. Use 5% polyvinylpyrrolidone K30 aqueous solution to make the above mixture into a soft material, use a 18-mesh sieve to wet-process granules, and dry the wet granules at 60° C. to obtain dry granules. After siz...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an oral compound pharmaceutic preparation for treating asthma, which contains tranilast shown as the formula (I) and salbutamol sulfate shown as the formula (II) or other pharmaceutically allowed active ingredients. The invention also relates to the application of compounds shown as formulas (I) and (II) or pharmaceutically allowed salts thereof in the preparation of an oral therapeutical agent for treating asthma.

Description

Field of invention: [0001] The invention relates to an oral therapeutic agent for asthma containing tranilast and salbutamol sulfate as active ingredients and the use of tranilast and salbutamol sulfate in preparing the oral therapeutic agent for asthma. Background technique: [0002] Research on respiratory diseases has progressed rapidly in the past 30 years, and the modern prevention and treatment of asthma has undergone major changes due to the in-depth study of the pathogenesis of asthma. In the past, it was believed that asthma was mainly IgE-mediated type I allergy: sensitized mast cells release granules that cause bronchial smooth muscle spasm and lead to reversible airway obstruction. The main treatment is the application of bronchodilators to relieve bronchospasm. At present, it is known that allergic inflammation of the airway is the main factor in the pathogenesis of asthma, which is far more harmful than airway smooth muscle spasm. Antiallergic drugs should be u...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/196A61K31/137A61K9/00A61P11/06
Inventor 王凌春高实张祥明
Owner 沈阳三川医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com